A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor.

Abstract

The purpose of this study was to evaluate the antitumor activity and tolerability of ifosfamide (IFO) at a dose of 3 g/m2, given on 2 consecutive days every 2 weeks, in advanced Wilms' tumor patients in whom conventional therapy had failed. Mesna and hyperhydration were concomitantly given to minimize bladder toxicity. A total of 21 patients with advanced Wilms' tumor were entered in the study. The response observed after two courses was complete in 6 patients and partial in 5; 10 did not respond; the median duration of response was 2 months (range, 1-7 months). Leucopenia caused a delay in therapy for 1 or 2 weeks in only three cases. Neither fever nor infection were observed. Of 7 patients who developed hematuria, 3 were among the 17 who concurrently received mesna. The urotoxicity did not interfere with subsequent therapy in these three cases.

• Authors: M F Tournade
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 24 Suppl 1 Pg. S31-3 ( 1989) ISSN: 0344-5704 [Print] Germany
• PMID: 2547529 (Publication Type: Journal Article)

Chemical References

• Mesna
• Ifosfamide

Topics

• Adolescent
• Adult
• Child
• Child, Preschool
• Drug Evaluation
• Drug Therapy, Combination
• Humans
• Ifosfamide (adverse effects, therapeutic use)
• Infant
• Kidney Neoplasms (drug therapy)
• Mesna (administration & dosage)
• Neoplasm Recurrence, Local (drug therapy)
• Remission Induction
• Time Factors
• Wilms Tumor (drug therapy)